CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sanitas AB is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sanitas AB
Veiveriu str. 134B
Phone: +370 37226725p:+370 37226725 KAUNAS, 46352  Lithuania Ticker: SAN1LSAN1L
This company was Merged or Acquired on 8/19/2011.
This is a Subsidiary, click here for the Parent Company
Business Summary
Sanitas AB (Sanitas JSC or Sanitas Group) is a Lithuania-based holding company engaged in the pharmaceutical industry. The Company's main activities include the production and sale of generic drugs, development of new products and contract manufacturing of pharmaceuticals. Its range of products comprises ampoules, tablets, ointments, injectables, eye drops, sterile powders and others. The Company’s research and development activity concentrates on the therapeutic areas of dermatology, ophthalmology, diabetology, urology, and hospital injectables. Sanitas AB operates through three wholly owned subsidiaries: Sanitas Pharma a.s. located in Slovakia, Jelfa SA and Laboratorium Farmaceutyczne Homeofarm sp. z o.o. located in Poland. In addition, it has one affiliated company, Valeant IPM sp. z o.o. As of December 31, 2011, the Company’s major shareholder was Valeant Pharmaceuticals International, Inc. with a stake of 99.4%.
(Source: ARS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/201312/31/2012Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Management Board Robert R.Chai-Onn 44 9/7/2011 9/7/2011
General Manager (CEO) Saulius M.Zemaitis 12/31/2011 12/31/2011
Member of the Management Board Seana-LynCarson 9/7/2011 9/7/2011
3 additional Officers and Directors records available in full report.

Business Names
Business Name
AB Sanitas
Emo-Farm Sp.z o.o.
Hoechst-Biotika spol. s r.o.
5 additional Business Names available in full report.

General Information
Number of Employees: 927 (As of 3/31/2013)
Outstanding Shares: 31,105,920 (As of 3/31/2013)
Shareholders: 225
Stock Exchange: VSE
Fax Number: +370 37223696


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, August 29, 2023